Lv1
20 积分 2025-07-04 加入
Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic
7小时前
求助中
Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials
7小时前
已完结
Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review
8小时前
已完结
Merrill, Joan T et al. “Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.” Arthritis and rheumatism vol. 62,1 (2010): 222-33. doi:10.1002/art.27233
27天前
已完结
Jobe, Modou et al. “Hypertension in Sub-Saharan Africa: Burden, Barriers and Priorities for Improving Treatment Outcomes.” Circulation research vol. 137,1 (2025): 106-118. doi:10.1161/CIRCRESAHA.124.323889
1个月前
已完结
Olowoyo, Paul et al. “Prevalence of hypertension in Africa in the last two decades: systematic review and meta-analysis.” Cardiovascular research vol. 121,12 (2025): 1815-1829. doi:10.1093/cvr/cvaf125
1个月前
已完结
Goorani, Samaneh et al. “Hypertension: A Continuing Public Healthcare Issue.” International journal of molecular sciences vol. 26,1 123. 26 Dec. 2024, doi:10.3390/ijms26010123
1个月前
已完结
Etchegaray-MoralesIvetetal.“EpidemiologyofsystemiclupuserythematosusinLatinAmerica.”Reumatologiaclinicavol.2010(2024):560-566
2个月前
已完结
The 2024 APLAR Consensus on the Management of Lupus Nephritis
2个月前
已完结
The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus
2个月前
已完结
皖公网安备34019202002308
